The authority advised consumers to stop taking the products immediately and consult a doctor if they feel unwell or are concerned about their health
Important Notice: This product is intended strictly for research purposes only
On December 19, 2024, tirzepatide was officially removed from the FDA drug shortage list
B12 support may be part of that conversation, but the right frequency and value of treatment depend on symptoms, labs, and provider guidance
8 Eli Lilly currently awaits approval for its Alzheimers treatment, Donanemab, which, if approved, is expected to achieve peak annual sales of $2.5 billion
As there are no human comparative or controlled studies of the newer peptides, nor any manufacturing controls, it is impossible for me as a physician to prescribe these peptides for my patients